Lexology September 17, 2024
As we enter into the final months of 2024, new developments in the administration of the 340B Drug Pricing Program signal that additional reform may be on the way. Although recent revisions to the 340B program’s administrative dispute resolution (ADR) process represented a positive development in program reform, many questions remain as to how the Health Resources and Services Administration (HRSA) along with Congress may resolve stakeholder concerns with the drug pricing program’s future.
The Rise of State 340B Contract Pharmacy Laws
The 340B Drug Pricing Program is a federal plan that allows covered entities to purchase outpatient drugs from manufacturers participating in Medicaid at discounted prices. As a condition of participation in the Medicaid program, drug manufacturers must sign...
Today's Sponsors
Today's Sponsor